Climate Change Data

三生国健(688336)

Climate Impact & Sustainability Data (2021, 2022-01 to 2022-06, 2023-01 to 2023-06)

Reporting Period: 2021

Environmental Metrics

Total Carbon Emissions:21,410.73 tCO2e/year
Scope 1 Emissions:4,540.01 tCO2e/year
Scope 2 Emissions:16,870.72 tCO2e/year
Total Energy Consumption:29,037.39 MWh/year
Water Consumption:361,473 m3/year
Waste Generated:86.48 tons/year (hazardous); 144.59 tons/year (non-hazardous)
Carbon Intensity:0.23 tCO2e/million Yuan

ESG Focus Areas

  • Company Governance
  • Research and Development in the Healthcare Industry
  • Reliable Antibody Drug Supply
  • Social Value Creation
  • Environmental Stewardship

Environmental Achievements

  • Achieved 100% compliance in pollutant discharge.
  • Greenhouse gas emissions (Scope 1 and 2): 21,410.73 tons of CO2e

Social Achievements

  • 公益投入 975.76 万元 (Public welfare investment of 9.7576 million Yuan)
  • “益+希望”白求恩 · 益赛普公益捐助项目惠及病患 20,733 人，援助药品 65,724 支 (“Yi+Hope” Baiqiuen Yisaipu Public Welfare Donation Project benefited 20,733 patients, providing 65,724 doses of medicine)
  • “普惠生命”白求恩 · 赛普汀公益捐助项目惠及病患 1,405 人，援助药品 10,821 支 (“Puhui Life” Baiqiuen Saiputin Public Welfare Donation Project benefited 1,405 patients, providing 10,821 doses of medicine)
  • Employee training coverage rate: 100%

Governance Achievements

  • Established a top-down ESG management framework.
  • Implemented a comprehensive compliance management system.
  • Strengthened anti-corruption and anti-money laundering management.

Climate Goals & Targets

Environmental Challenges

  • Climate change related risks (physical and transition risks)
  • Supply chain risks
  • Maintaining high quality standards in a rapidly evolving industry
Mitigation Strategies
  • Developed alternative sourcing strategies
  • Implemented robust quality control and risk management systems
  • Established a crisis event early warning system
  • Strengthened supplier audits and responsible procurement practices

Supply Chain Management

Supplier Audits: 69 audits/year

Responsible Procurement
  • Supplier Code of Conduct
  • Anti-corruption and anti-bribery commitments

Climate-Related Risks & Opportunities

Physical Risks
  • Extreme weather events
  • Flooding
Transition Risks
  • Regulatory changes
  • Market shifts
Opportunities
  • Development of energy-efficient products

Reporting Standards

Frameworks Used: TCFD

Certifications: ISO 14001:2018, ISO 45001:2018

Reporting Period: 2022-01 to 2022-06

Environmental Metrics

ESG Focus Areas

  • Quality Management
  • ESG Management

Social Achievements

  • Published its first ESG report, among the first in the Sci-Tech Innovation Board pharmaceutical companies.
  • Achieved a B+ rating in the latest Shangdao Ronglv ESG rating, ranking among the top 12.5% of all A-share companies.
  • Won the Pudong New Area District Mayor Quality Award in the second Pudong New Area Government Quality Award.

Climate Goals & Targets

Environmental Challenges

  • Impact of the epidemic and competitive environment on sales of Yisaipu in the first half of 2022.
Mitigation Strategies
  • Multi-dimensional exploration and active response to changes, including expanding new dosage forms, actively responding to volume-based procurement, strengthening brand effects, and promoting the concept of chronic diseases.

Supply Chain Management

Climate-Related Risks & Opportunities

Awards & Recognition

  • Pudong New Area District Mayor Quality Award

Reporting Period: 2023-01 to 2023-06

Environmental Metrics

Total Carbon Emissions:Not disclosed
Scope 1 Emissions:Not disclosed
Scope 2 Emissions:Not disclosed
Scope 3 Emissions:Not disclosed
Renewable Energy Share:Not disclosed
Total Energy Consumption:Not disclosed
Water Consumption:Not disclosed
Waste Generated:Not disclosed
Carbon Intensity:Not disclosed

ESG Focus Areas

  • Climate Change
  • Social Responsibility
  • Corporate Governance

Environmental Achievements

  • Achieved a CDP Climate Change rating of B, exceeding 72% of mainland China companies with disclosed CDP ratings.

Social Achievements

  • Participated in and supported the "Ankylosing Spondylitis Health Poverty Alleviation Project" and the "Ankylosing Spondylitis Healthy Village Project", training over 28,356 medical personnel and conducting 747 training and outreach events.
  • Achieved an A- rating in the latest Shangdao Ronglv ESG rating, ranking in the top 6.3% of all rated companies.

Governance Achievements

  • Not disclosed

Climate Goals & Targets

Long-term Goals:
  • Not disclosed
Medium-term Goals:
  • Not disclosed
Short-term Goals:
  • Not disclosed

Environmental Challenges

  • Not disclosed
Mitigation Strategies
  • Not disclosed

Supply Chain Management

Supplier Audits: Not disclosed

Responsible Procurement
  • Not disclosed

Climate-Related Risks & Opportunities

Physical Risks
  • Not disclosed
Transition Risks
  • Not disclosed
Opportunities
  • Not disclosed

Reporting Standards

Frameworks Used: CDP

Certifications: Null

Third-party Assurance: Not disclosed

UN Sustainable Development Goals

  • Not disclosed

Not disclosed

Sustainable Products & Innovation

  • Not disclosed

Awards & Recognition

  • Not disclosed